REGULATORY

Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel

November 7, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on November 6 backed approval for a batch of medicines including Sanofi’s blockbuster hopeful dupilumab and Chugai Pharmaceutical’s anti-PD-L1 antibody atezolizumab. The Pharmaceutical Affairs and Food Sanitation…

To read the full story

MHLW OKs Dupixent, Tecentriq, Lynparza, and More
January 22, 2018

REGULATORY

Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
March 9, 2026
Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026
Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…